Toxoplasma gondii in individuals with schizophrenia: Association with clinical and demographic factors and with mortality

Schizophrenia Bulletin

Volumn 33, Issue 3, 2007, Pages 737-740

  Dickerson, Faith ^a   Boronow, John ^a   Stallings, Cassie ^a   Origoni, Andrea ^a   Yolken, Robert ^b  

^a SHEPPARD PRATT HEALTH SYSTEM   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Infection; Mortality; Parasite

Indexed keywords

IMMUNOGLOBULIN G; PROTOZOON ANTIBODY;

ADULT; ARTICLE; CONFIDENCE INTERVAL; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENDER; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; RACE; RISK ASSESSMENT; SCHIZOPHRENIA; SCORING SYSTEM; SEROLOGY; TOXOPLASMA GONDII; TOXOPLASMOSIS; ANIMAL; BLOOD; CAUSE OF DEATH; EPIDEMIOLOGY; MIDDLE AGED; PARASITOLOGY; PSYCHOLOGY; RISK FACTOR; STATISTICS; TOXOPLASMA; UNITED STATES;

ADULT; ANIMALS; ANTIBODIES, PROTOZOAN; CAUSALITY; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MARYLAND; MIDDLE AGED; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STATISTICS; TOXOPLASMA; TOXOPLASMOSIS, CEREBRAL;

EID: 34548042322     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbm005     Document Type: Article

References (14)

1. Torrey EF. Are we overestimating the genetic contribution to schizophrenia? Schizophr Bull. 1992;18:159-170.
2. Fan JB, Zhang CS, Gu NF, et al. Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis. Biol Psychiatry. 2005;57:139-144.
3. Mortensen PB, Norgaard-Pedersen B, Waltoft BL, et al. Toxoplasma gondii as a risk factor for early-onset schizophrenia: analysis of filter paper blood samples obtained at birth. Biol Psychiatry. 2006, in press.
4. Brown AS, Schaefer CA, Quesenberry CP Jr, Liu L, Babulas VP, Susser ES. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am J Psychiatry. 2005;162:767-773.
5. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150:1115-1121.
6. Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005;66:183-194.
7. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry. 2006;188:122-127.
8. Dickerson FB, Boronow JJ, Stallings CR, Origoni AE, Yolken RH. Reduction of symptoms by valacyclovir in cytomegalovirus-seropositive individuals with schizophrenia. Am J Psychiatry. 2003;160:2234-2236.
9. Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20:310-319.
10. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
11. Jones JL, Kruszon-Moran D, Wilson M. Toxoplasma gondii infection in the United States, 1999-2000. Emerg Infect Dis. 2003;9:1371-1374.
12. Lindova J, Novotna M, Havlicek J, et al. Gender differences in behavioural changes induced by latent toxoplasmosis. Int J Parasitol. 2006;36:1485-1492.
13. Yereli K, Balcioglu IC, Ozbilgin A. Is Toxoplasma gondii a potential risk for traffic accidents in Turkey? Forensic Sci Int. 2006;163:34-37.
14. Flegr J, Havlicek J, Kodym P, Maly M, Smahel Z. Increased risk of traffic accidents in subjects with latent toxoplasmosis: a retrospective case-control study. BMC Infect Dis. 2002;2:art-11.